reBrain – heale meeleolule, ajutegevusele, mälule
Tuntud ajueksperdid dr. Avner Scheinfeld ja professor Meir Szynicki uurisid ajurakke ja eriti neid ümbritsevaid ja kaitsvaid membraane. Nad avastasid koos oma uurimisrühmaga, et membraanide tervise ning meie mälu, probleemide lahendamise võimete, emotsioonide ja muude põhioskuste vahel on otsene seos ning et ajurakke ja nende membraane tuleb aju sujuvaks toimimiseks pidevalt teatud mikroelementidega toita.
reBRAIN on uue põlvkonna nootroopne toidulisand vaimse tervise ja hea psühholoogilise funktsiooni jaoks. Mõiste “nootroopne” pärineb kahest kreekakeelsest sõnast: “noos” tähendab mõistust, mõtlemist ja mõtteid ning “tropos” tähendab kalduvust, pööret, viisi.
Meie närvisüsteem koosneb kahest põhiosast: kesknärvisüsteemist ja perifeersest närvisüsteemist. Mõlemad süsteemid on seotud signaalide saatmisega aju ja teiste kehaosade vahel, kontrollides seeläbi meie keha funktsioone: normaalset hingamist, mõtlemist, liikumist. Aja jooksul muutub aga meie mälu vähem teravaks, mõtlemine aga vähem selgeks.
reBRAIN on nootroopne toidulisand, mille toimeainete kliinilised uuringud on tõestanud, et need toetavad üldist ajutegevust, parandavad mälu, keskendumisvõimet, mõtete selgust ja elukvaliteeti. reBRAIN´i koostises sisalduvad fosfatidüülseriin (PS) ja fosfatiidhape (PA) on ained, mida pidevalt uuritakse, tõestamaks, kuidas need mõjutavad närvirakkude membraane. Kliinilised uuringud on näidanud positiivset mõju katsealuste mälule, keskendumisvõimele, meeleolule ja kognitiivsele funktsioonile.
10 rahvusvahelist patenti.
6 kliinilist uuringut.
25 aastat kogemust.
Kliiniliste uuringute tulemused on näidanud, et reBRAIN´i koostises sisalduvad fosfolipiidid võivad aidata säilitada kognitiivset funktsiooni ja teravat mälu, samas kui MCT õlil – meie ajutegevuse „kütusel“ – on seos inimese üldise psühholoogilise funktsiooni, mälu, otsustusvõime ja mõtete väljendamisega.
Ajakirjas The Journal of Alzheimer’s Disease** avaldatud uuringus tõestati, et glütseriidid võivad tõsta dopamiini taset ja parandada meeleolu ning on eriti kasulikud Alzheimeri tõve põdevate patsientide kognitiivsele funktsioonile.
TOIMEAINED:
Fosfatidüülseriin ja fosfatiidhape on meie ajus looduslikult leiduvad fosfolipiidid. Fosfolipiididel on oluline roll rakumembraanide kaitsmisel kahjustuste eest ja rakkudevahelise suhtluse kergendamisel.
Aja jooksul nende lipiidide hulk järk-järgult väheneb. Uuringus „Progress in Lipid Research“ tehti kindlaks, et inimestel, kellel on tõsiseid kognitiivseid häireid, võib fosfolipiidide tarbimine parandada mälu ning kognitiivset funktsiooni.
Keskmise ahela triglütseriidid (MCT õli, inglise keeles middle chain triglycerides) on keskmise pikkusega rasvhapete ahela keskmise ahela triglütseriidid, mida leidub õlides. MCT on meie kehas kõige levinum rasvatüüp. MCT-d satuvad otse meie maksa, seega on selle aine imendumine palju kiirem ja maksal tuleb teha minimaalseid pingutusi, et MCT muutuks energiaks ja ketoonideks. Ketoonid on tõhusam ja stabiilsem energiaallikas kui glükoos. Uuringus (The Journal of Alzheimer’s Disease) märgati, et mõõduka kuni raske Alzheimeri tõvega patsientidel võib ketoonide tootmise suurendamine aidata parandada psühholoogilist funktsiooni ja mälu, otsustusvõimet ja loogilist mõtlemist.
Glütseriidid on glütserooli rasvhappeestrid, mis on üks peamisi lipiidide klasse ja hõlmavad suuremat osa loomseid rasvu ja taimseid õlisid ning mida leidub tavaliselt tserebrospinaalvedelikus. Arvatakse, et need võivad parendada kognitiivset funktsiooni, tõsta dopamiini taset ja parandada meeleolu.
reBRAIN
Ühes pakendis 60 kapslit = 1 kuu kuur!
Kasutamine: täiskasvanutele 2 kapslit päevas söögi ajal või pärast sööki koos klaasitäie veega. Lastele alates 7. eluaastast 1 kapsel päevas. Toidulisandit on soovitatav manustada kuni 3 kuud.
| Sisaldus | 2 kapslit | NRV* |
| Soja fosfatidüülseriin | 200 mg | – |
| Soja fosfatiidhape | 200 mg | |
| Keskmise ahelaga triglütseriidid(MCT õli), glütseriidid | 780 mg | – |
*NRV – Päevane võrdluskogus täiskasvanule
Koostisosad: fosfolipiidide kompleks sojaletsitiinist (fosfatidüülseriin (PS)), fosfatiidhape (PA), keskmise ahelaga triglütseriidid (MCT õli), želatiin, glütserool, värvaine, raudoksiid, vesi.
Hoiatused: Toidulisand! Mitte ületada päevaseks tarbimiseks soovitatud annust. Toidulisand ei asenda mitmekülgset ja tasakaalustatud toitumist ega tervislikku eluviisi.
UURINGUD JA TULEMUSED
Toidulisandis sisalduvate toimeainete mõju mälule, tunnetusele, igapäevasele tegevusele ja meeleolule viidi läbi kahekordse platseebokontrolliga uuringu käigus. Katsealused polnud haiged, kuid halvenenud vaimse aktiivsuse ja psühholoogilise funktsiooni üle kaebavad inimesed.
Selles uuringus hinnati juhuslike proovidega ka toidulisandi toimeainete mõju Alzheimeri tõbe põdevate patsientide igapäevastele tegevustele, vaimsele tervisele ja emotsionaalsele seisundile.
Kliiniline uuring näitas, et toidulisandi toimeainete igapäevane tarbimine avaldas positiivset mõju Alzheimeri tõve ja dementsusega eakatele patsientidele, samuti märgati mõju mälule, keskendumisvõimele, meeleolule ja kognitsioonile.
Kaks kliinilist uuringut näitasid aju tervise ja vaimse jõudluse paranemist vanemaealistel patsientidel ja Alzheimeri tõve või dementsusega patsientidel.
3 kuud kestnud topeltpimedas platseebokontrollitud uuringus, milles kasutati Wechsler´i mäluskaalat ja depressiivsete sümptomite loendit, hinnati toidulisandis sisalduvate toimeainete mõju mälule ja meeleolule funktsioneerivatel, mitte haigetel, kuid mäluprobleemidega eakamatel inimestel.
2 kuud väldanud randomiseeritud topeltpimedas platseebokontrollitud uuringus hinnati mõju igapäevasele tegevusele (st seitsmele igapäevaelu tegevusele), vaimsele tervisele, emotsionaalsele seisundile ja Alzheimeri tõve üldisele seisundile ning Alzheimeri tõvega patsientidele.
Uuringu tulemustest võib järeldada, et toidulisand parandas mälu ja hoidis ära kaamosest põhjustatud sümptomid. Näitas positiivset mõju eakate inimeste meeleolule ja tunnetusele. Toidulisandite lühiajaline andmine Alzheimeri tõvega patsientidele näitas stabiliseerivat toimet igapäevasele tegevusele, emotsionaalsele seisundile ja üldisele heaolule.
*Positive Effects of Soy Lecithin-Derived Phosphatidylserine plus Phosphatidic Acid on Memory, Cognition, Daily Functioning, and Mood in Elderly Patients with Alzheimer’s Disease and Dementia“
**Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease, Journal: Journal of Alzheimer’s Disease, vol. 64, no. 2, pp. 551-561, 2018
MUUD UURINGUD
Positive Effects of Soy Lecithin-Derived Phosphatidylserine plus Phosphatidic Acid
on Memory, Cognition, Daily Functioning, and Mood in Elderly Patients with Alzheimer’s
Disease and Dementia
Introduction
We report previously unpublished, early pilot studies performed with a brain-health food supplement containing a proprietary blend of 100 mg phosphatidylserine (PS) and 80 mg phosphatidic acid (PA) produced from soy lecithin.
Methods
Serum analysis after single PS+PA ingestion was performed in healthy volunteers. A 3-month double-blind, placebo-controlled study assessed the influence of three PS+PA capsules/day, (300 mg PS + 240 mg PA/day) or placebo on memory and mood in functioning, non-depressive elderly people with memory problems, using the Wechsler Memory Scale and the List of Depressive Symptoms. Furthermore, a 2-month randomized, double-blind, placebo-controlled trial assessed the effect of three PS+PA capsules/day (300 mg PS + 240 mg PA/day) or placebo on daily functioning, mental health, emotional state, and self-reported general condition in patients with Alzheimer’s disease (AD).
Results
Serum PS peaked 90 min after ingestion, returning to baseline after 180 min. In the elderly, PS+PA [per protocol (PP) n = 31], unlike placebo (PP n = 26), significantly improved memory and prevented “winter blues” in a pre–post comparison. In the patients with AD, daily functioning (i.e., 7 activities of daily living) under PS+PA (PP n = 53) remained unchanged, but declined from 5.62 to 4.90 under placebo (PP n = 39; P = 0.035), with significant group difference (P = 0.021). The PS+PA group had 3.8% deterioration and 90.6% stability in daily functioning, compared to 17.9% and 79.5% under placebo, respectively (P = 0.066). Forty-nine percent of the PS+PA patients reported an improved general condition, compared to 26.3% under placebo (P = 0.084). Approximately, 43% of the PS+PA patients, but none under placebo, continued post-trial supplementation (while double-blinded). No negative side effects were observed.
Conclusion
PS is efficiently absorbed after oral consumption. A positive influence of PS+PA on memory, mood, and cognition was demonstrated among elderly test subjects. Short-term supplementation with PS+PA in patients with AD showed a stabilizing effect on daily functioning, emotional state and self-reported general condition. The data encourage long-term studies with PS+PA in AD patients and other elderly with memory or cognition problems.
A soy-based phosphatidylserine/ phosphatidic acid complex (PAS) normalizes the stress
reactivity of hypothalamus-pituitary-adrenalaxis in chronically stressed male subjects: a
randomized, placebo-controlled study
Authors: Margret I. Moré, Ulla Freitas, and David Rutenberg
ABSTRACT
Background
Supplementation with a phosphatidylserine and phosphatidylserine/ phosphatidic acid complex (PAS) has been observed to normalize stress induced dysregulations of the hypothalamuspituitary- adrenal axis (HPAA). Prolonged stress first induces a hyper-activation of the HPAA, which then can be followed by a state of hypo-activation.The aim of this study was to examine effects of an oral supplementation with 400 mg PS & 400 mg PA (PAS 400) per day on the endocrine stress response (ACTH, saliva and serum cortisol) to a psychosocial stressor. A special focus was to analyze subgroups of low versus high chronically stressed subjects as well as to test efficacy of 200 mg PS & 200 mg PA (PAS 200).
Methods
75 healthy male volunteers were enrolled for this double-blind, placebo-controlled study, stratified by chronic stress level, and randomly allocated to one of three study arms (placebo, PAS 200 and PAS 400 per day, respectively). Study supplementation was administered for 42 days for each participant. Chronic stress was measured with the Trier Inventory for Chronic Stress (TICS), and subgroups of high and low chronic stress were differentiated by median values as provided by the TICS authors. A six week period of supplementation was followed by an acute stress test (Trier Social Stress Test – TSST).
Results
Chronic stress levels and other baseline measures did not differ between treatment groups (all p>0.05). Acute stress was successfully induced by the TSST and resulted in a hyper-responsivity of the HPAA in chronically stressed subjects. Compared to placebo, a supplementation with a daily dose of PAS 400 was effective in normalizing the ACTH (p=0.010), salivary (p=0.043) and serum cortisol responses (p=0.035) to the TSST in chronically high but not in low stressed subjects (all p>0.05). Compared to placebo, supplementation with PAS 200 did not result in any significant differences in these variables (all p>0.05). There were no significant effects of supplementation with PAS on heart rate, pulse transit time, or psychological stress response (all p>0.05).
Conclusion
In chronically stressed subjects, a supplementation with PAS 400 (MemreePlus™) can normalize
the hyper-responsivity of the HPAA to an acute stressor.
Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the
endocrine and psychological responses to mental stress
Authors: Juliane Hellhammer, Dominic Vogt, Nadin Franz, Ulla Freitas, David Rutenberg
ABSTRACT
Phosphatidylserine, derived from cow brains, has been shown previously to dampen the ACTH and cortisol response to physical stress. Further research investigated the influence of soy lecithin phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. In this study, we investigated the effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) supplementation on pituitary adrenal reactivity (ACTH, cortisol) and on the psychological response (Spielberger State Anxiety Inventory stress subscale) to a mental and emotional stressor. Four groups of 20 subjects were treated for three weeks with daily dosages of either 400 mg PAS, 600 mg PAS, 800 mg PAS, or placebo before exposure to the Trier Social Stress Test (TSST). Treatment with 400 mg PAS resulted in a pronounced blunting of both serum ACTH and cortisol, and salivary cortisol responses to the TSST, but did not affect heart rate. The effect was not seen with larger doses of PAS. With regard to the psychological response, 400 mg PAS seemed to exert a specific positive effect on emotional responses to the TSST. While the placebo group showed the expected increase in distress after the test, the group treated with 400 mg PAS showed decreased distress. These data provide initial evidence for a selective stress dampening effect of PAS on the pituitary-adrenal axis, suggesting the potential of PAS in the treatment of stress related disorders.
A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): Results of a randomized, placebo-controlled, double-blind clinical trial
Authors: Hellhammer, E. Fries, C. Buss, V. Engert, A. Tuch, D. Rutenberg, D. Hellhammer
ABSTRACT
Background & aims
Many women experience emotional and physical symptoms around the time of ovulation and more so before menstruation interfering with their daily normal life also known as premenstrual syndrome (PMS). Recent observational data suggest that supplementation with Lipogen’s phosphatidylserine (PS) and phosphatidic acid (PA) complex (PAS) alleviates these PMS symptoms. The aim of this study was to confirm these observations on the effects of PAS on PMS symptom severity within a controlled clinical trial setting.
Methods
Forty women aged 18-45 years with a diagnosis of PMS were assigned to either take PAS (containing
400 mg PS & 400 mg PA per day) or a matching placebo. The study comprised 5 on-site visits including 1 baseline menstrual cycle followed by 3 treatment cycles. Treatment intake was controlled for by using an electronic device, the Medication Event Monitoring System (MEMS®). Primary outcome of the study was the PMS symptoms severity as assessed by using the Daily Record of Severity of Problems (DRSP). Further, SIPS questionnaire (a German version of the Premenstrual Symptoms Screening Tool (PSST)), salivary hormone levels (cortisol awakening response (CAR) and evening cortisol levels) as well as serum levels (cortisol, estradiol, progesterone and corticosteroid binding globulin (CBG)) were assessed.
Results
PMS symptoms as assessed by the DRSP Total score showed a significantly better improvement (p = 0.001) over a 3 cycles PAS intake as compared to placebo. In addition, PAS treated women reported a greater improvement in physical (p = 0.002) and depressive symptoms (p = 0.068). They also reported a lower reduction of productivity (p = 0.052) and a stronger decrease in interference with relationships with others (p = 0.099) compared to the placebo group. No other DRSP scale or item showed significant results. Likewise, the reduction in the number of subjects fulfilling PMS or premenstrual dysphoric disorder (PMDD) criteria as classified by the SIPS did not differ between the PAS and the placebo group. For the biomarkers, the salivary cortisol percentage increase of the CAR was significantly less pronounced in the follicular phase of cycle 4 than in the follicular phase of cycle 1 for subjects taking PAS when compared to subjects taking placebo (p = 0.018). Furthermore, the change of serum cortisol levels between visit 1 and visit 5 differed significantly between groups (p = 0.043). While serum cortisol levels of PAS treated females slightly decreased between visit 1 and visit 5, cortisol levels of females treated with placebo increased. For all other biomarkers, no treatment effects were observed over the 4 cycles study period. Overall, this study confirms that a daily intake of PAS, containing 400 mg PS and 400 mg PA, can be considered as safe.
Conclusions
Results substantiate the efficacy of PAS in reducing symptoms of PMS. In view of the recent inclusion
of severe PMS symptoms (PMDD) in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the positive results of this clinical study merits consideration of developing the PAS complex as a botanical drug for treatment of PMDD.